FMP

FMP

Enter

Wolfe Research Slightly Raises Coterra Energy Price Target

-

twitterlinkedinfacebook
blog post cover photo

Image credit: FMP

Wolfe Research analysts increased their price target for Coterra Energy (NYSE:CTRA) to $32 from $31, maintaining an Outperform rating on the stock. The revision reflects optimism surrounding Coterra’s recent acquisitions and potential for improved performance relative to the energy sector.

Year-to-date, Coterra has underperformed the Russell 3000 Energy Index by approximately 10%, partly due to market speculation about a possible acquisition in the Anadarko Basin. However, the company’s recent bolt-on acquisitions in the Permian Basin appear to have quelled those rumors. These transactions have strengthened its drilling inventory in New Mexico, positioning Coterra to capitalize on operational efficiencies and bolster its performance.

Wolfe Research anticipates that Coterra’s updated three-year outlook, expected with its year-end results, could serve as a catalyst for resetting medium-term free cash flow growth expectations.

Wolfe’s base case scenario, which assumes long-term prices of $65 WTI and $4.00 Henry Hub gas with an 8% cost of capital, suggests potential value upside for the company. As Coterra integrates its newly acquired assets and begins to execute on operational efficiencies, the outlook for its relative performance appears increasingly favorable.

Other Blogs

Nov 14, 2024 7:25 AM - Davit Kirakosyan

Citi Initiates Neutral Coverage on CSW Industrials Amid Balanced Growth and Valuation Risks

Citi analysts initiated coverage on CSW Industrials (NASDAQ:CSWI) with a Neutral rating and a price target of $466.00. The evaluation reflects confidence in the company’s strong business fundamentals but acknowledges potential risks tied to its valuation and market conditions. CSW Industrials has de...

blog post title

Nov 14, 2024 7:34 AM - Davit Kirakosyan

Citi Starts Neutral Coverage on Biogen Stock

Citi analysts initiated coverage on Biogen (NASDAQ:BIIB) with a Neutral rating and a price target of $190 on the stock. The assessment reflects a balance between the company’s recent launches and ongoing challenges in its legacy franchises. Biogen’s core revenue drivers, including its multiple scler...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep